Overview
A Thrombophilia Profile is a laboratory panel used to detect disorders that cause abnormal blood clot formation, known as thrombosis. The profile evaluates both inherited and acquired clotting risks. It helps identify individuals at risk for deep vein thrombosis and pulmonary embolism.
The panel includes testing for genetic mutations such as Factor V Leiden and Prothrombin G20210A, functional deficiencies of Protein C, Protein S, and Antithrombin III, and acquired autoimmune conditions such as antiphospholipid syndrome. Early detection supports proactive anticoagulation strategies and helps prevent life-threatening thrombotic events.
Symptoms
Thrombophilia may present with recurrent or unexplained blood clots, including deep vein thrombosis and pulmonary embolism. Warning signs include leg pain or swelling, shortness of breath, chest pain, severe headache, visual disturbances, and unusual limb swelling.
In pregnancy, thrombophilia is clinically significant because pregnancy is naturally a hypercoagulable state. Affected patients may experience recurrent pregnancy loss, intrauterine growth restriction, preeclampsia, or placental abruption. Monitoring is essential to ensure maternal and fetal safety.
Causes
Thrombophilia may be hereditary or acquired. Hereditary causes include Factor V Leiden mutation, Prothrombin G20210A mutation, Protein C deficiency, Protein S deficiency, and Antithrombin deficiency. These conditions impair the natural anticoagulant pathways and increase the risk of clot formation.
Acquired causes include antiphospholipid syndrome, lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein antibodies. Elevated homocysteine levels due to metabolic or genetic factors, including MTHFR mutation, also contribute to thrombotic risk. Risk may increase during pregnancy, the postpartum period, immobilization, or malignancy. Testing identifies both genetic and functional abnormalities that influence clotting balance.
Risk Factors
Indications for testing include recurrent thrombosis, clot formation before fifty years of age, thrombosis at unusual sites, recurrent pregnancy loss, late fetal loss, early severe preeclampsia, and a strong family history of venous thromboembolism.
Pregnancy and the postpartum period increase risk due to physiological hypercoagulability. Active clotting episodes and anticoagulant therapy may interfere with testing accuracy. Warfarin lowers Protein C and Protein S levels, heparin affects Antithrombin levels, and direct oral anticoagulants interfere with clot-based assays. Temporary changes such as recent surgery, infection, or pregnancy may alter protein levels and cause misleading results.
Prevention
Proper timing of testing is essential. Evaluation should be avoided during acute clotting events or while on anticoagulant therapy to prevent false interpretations. Functional tests are ideally performed at least three months after an acute event and two to four weeks after stopping anticoagulants.
Genetic tests for Factor V Leiden and Prothrombin mutation can be performed at any time because DNA markers are stable. Appropriate patient preparation, medication disclosure, and hydration improve test reliability. Identification of thrombophilia allows individualized anticoagulation management, especially in high-risk individuals and pregnant patients.
Despite its value, interpretation can be challenging due to temporary changes, medication effects, and the fact that a positive mutation does not always guarantee a clot. Results must be integrated with clinical history to guide prevention and long-term management.
